In the evolving field of biochemical research, the pepti by H Daghero · 2020 · Cited by 12 — CIGB-552 is a synthetic anti-tumor peptide capable of reducing tumor size and increasing the lifespan of tumor-bearing mice. de CIGB-552 has emerged as a subject of significant interest for those tracking advancements in synthetic amino acid chains. As someone who follows developments in molecular biology and biotechnology, I have found the structural complexity and functional properties of this specific compound to be quite remarkable.
Understanding the Structure of CIGB-552
At its core, CIGB-552 is a twenty-amino-acid novel synthetic peptide. It is classified as a second-generation peptide CIGB-552, which signifies an evolution in design compared to its predecessor, the L-2 peptide. Developed at the Center for Genetic Engineering and Biotechnology, the molecular architecture of this compound allows it to function as a cell-penetrating peptide. This ability to traverse cellular membranes is a critical feature that differentiates i by BM Oliva · 2013 · Cited by 1 — We found that CIGB-552 induces ubiquitination of RelA and inhibits the anti-apoptotic genes regulated by NF-kB whereas knockdown of COMMD1 blocks this effect. t from simpler compounds.
When reviewing the technical literature, it is clear that CIGB-552 is a synthetic peptide designed with specific biochemical interactions in mind. One of the Peptide CIGB-552 has a synergistic effect on CFTR- most frequently cited mechanisms is that CIGB-552 increases the levels of the protein COMMD1. By upregulating this protein, the peptide is able to interact with internal cellular pathways CIGB-552: A new penetrating peptide with antitumor action in a highly targeted manner.
Biochemical Mechanisms and Observations
My interest in this 552 peptide grew after reading about its impact on cellular regulation. For instance, research indicates that CIGB-552 induces ubiquitination of RelA, a process that effectively modulates the activity of the NF-kB pa by NA Gómez Hernández · 2026 — The CIGB-552 peptide is a novel therapeutic alternative for the treatment of cancer. In this study, we aimed to determine the optimal thway. Furthermore, the molecule acts as a new targeted anticancer therapy in experimental settings, showing potential in laboratory models where it has been observed to reduce tumor size and extend the lifespan of subjects.
From a pharmacokinetic perspective, the data is equally compelling. Studies show that CIGB-552 exhibits rapid absorption (within 15 min), which is essential for its observed activity profiles. It maintains a typical extravascular administration profile followed by a swift distribution phase. With a reported half-life ranging between 1.76 and 4.62 hours, the CIGB-552 mo CIGB-552 peptide lecule is optimized for specific, frequent dosing regimens in controlled research environments.
Synergistic Potential and Modern Research
Beyond its primary functions, there is growing intrigue regarding how this compound interacts with other agents. Recent reports suggest that CIGB-552 synergised with ETI In Vivo Evaluation of the Antitumor Peptide CIGB- 552: , enhancing CFTR-F508del-mediated chloride efflux. This CIGB-552 synergy with the tri-therapy highlights the versatility of this CIGB derivative, suggesting that its utility might extend beyond initial expectations.
As a second-generation synthetic anticancer peptide, its development has been rigorous. Whether it is classified as a synthetic anti-tumor peptide or simply a 552 molecule, the consistency of the findings—such as its role in increasing reactive oxygen species (ROS) and its interaction with COMMD1—remains a cornerstone of its profile.
Conclusion on CIGB-552
Whether you are looking at it as a CIGB-552 or a broader Synthetic Peptide CIGB-552, the compound represents a sophisticated achievement in synthetic biology. It is important to note that this information is intended for educational purposes regarding the chemical properties and research status of the molecule. It has been developed as a candidate to cancer treatment within the framework of rigorous clinical trials, such as the first-in-human phase I studies, which focused on safety and pharmacokinetic parameters.
For those of us observing the progress of the CIGB-552 peptide, the focus remains on its unique ability to penetrate cells and modulate protein levels, positioning it as a significant entity in the study of modern biochemistry.